echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Chinese pharmaceutical companies, global market development is imminent

    Chinese pharmaceutical companies, global market development is imminent

    • Last Update: 2020-01-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical network market analysis] in recent years, with the continuous promotion of policies such as medical insurance fee control and volume purchase, the industry concentration has been increasing, and the pharmaceutical pattern has changed significantly In addition to the head enterprises are expected to get better development opportunities, many pharmaceutical enterprises are gradually on the road of being eliminated, merged and even become pharmaceutical enterprises' processing plants At present, in the era of new medical insurance, the internal pressure of policies and social requirements for drug price reduction will not abate in a short period of time; coupled with the external pressure of the entry of multinational pharmaceutical enterprises such as India, Chinese pharmaceutical enterprises can be said to face double pressure Under all kinds of pressure, how can pharmaceutical enterprises achieve better development? In this regard, some industry experts pointed out that for Chinese pharmaceutical companies, the development of the global market is imminent At the same time, he also pointed out that the medical insurance under the supervision of the medical insurance bureau is not the whole content of China's medical insurance, and pharmaceutical companies can take a broader perspective In fact, with one country's "one belt, one road" initiative and the "going global" strategy, the market share of domestic pharmaceutical companies is expanding gradually in the process of internationalization I have learned that there are many domestic pharmaceutical enterprises on the way of internationalization For example, Hengrui pharmaceutical has always taken the international layout as an important strategy for high-quality development Since 2005, the oxaliplatin API of Hengrui pharmaceutical has obtained the EU CEP certification, and started to stride towards internationalization Up to 2019, we will continue to strengthen the implementation of international strategy and actively expand overseas market At present, many overseas application projects have been reported frequently In terms of the internationalization of generic drugs, Evergrande's ivabradine sulfate tablets have been approved in the UK, Germany and the Netherlands In addition, in the first half of this year, one API application was submitted to the US FDA and one API application was submitted to New Zealand In the aspect of internationalization of innovative drugs, the first-line clinical trial of anti-PD-1 antibody shr-1210 combined with apatinib mesylate was carried out orderly At present, Hengrui pharmaceutical has been approved in Europe, America and Japan for 18 preparation products, including injection, oral preparations and inhalation anesthetics It is worth mentioning that under the background of the accelerated pace of "going out" of Chinese enterprises, the performance of Sinopharm group is also very bright On December 20, 2019, it announced that the U.S Food and Drug Administration (FDA) has approved the listing application (NDA) of L-amlodipine maleate tablets (trade name: Xuanning) for the treatment of hypertension Not only has it become the first China's indigenous innovation approved by FDA, but it also means that the product is licensed to sell in the world In addition, Sinopharm group is also going to sea through various forms, including product acquisition, technology transfer, etc In the future, the internationalization path of Sinopharm group will gradually transform from product output to capital output, introduce overseas advanced technology and resources into China through international expansion, combine the application of local market, and then seek the expansion of overseas market Nowadays, internationalization strategy has become one of the important development strategies of local pharmaceutical enterprises In the future, pharmaceutical companies should pay attention to overseas layout in advance to achieve the simultaneous listing of new products at home and abroad In addition, pharmaceutical enterprises should also actively carry out diversified operation, carry out vertical expansion of business segments, and achieve diversified development.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.